The total return over the past 12 months is +50.19% vs. +16.94% for the S&P 500. So far it's up -17.11% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +50.19% | (23.09%) | (50.16%) | N/A | N/A | N/A |
| Total Return CAGR | +50.19% | (23.09%) | (50.16%) | N/A | N/A | N/A |
| Revenue CAGR | (100.00%) | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | (7.98%) | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | (50.57%) | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
SAB Biotherapeutics, Inc. (SABS)
| Year | Start price | End price | SABS Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $3.74 | $3.10 | (17.11%) | +14.51% | (31.62%) |
| 2025 | $3.79 | $3.74 | (1.32%) | +17.72% | (19.04%) |
| 2024 | $6.88 | $3.79 | (44.91%) | +24.89% | (69.80%) |
| 2023 | $5.90 | $6.88 | +16.63% | +26.19% | (9.56%) |
| 2022 | $78.10 | $5.90 | (92.45%) | (18.17%) | (74.28%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
